Administration of AAV2/9-Endo-Glo1 five weeks after HIV-1 infection blunted the increase in interstitial and perivascular fibrosis seen after 17 weeks post-infection (Figure 6C). The gene discussed is GLO1; the disease is HIV-1 infection.